Breaking News

Pfizer’s Cresemba Sales Trigger $26M Milestone to Basilea

Basilea remains eligible for milestones of up to approximately CHF 515 million, in addition to royalties on sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company focused on severe bacterial or fungal infections, reported that sales of the antifungal Cresemba (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling $26.25 million to Basilea.   David Veitch, Chief Executive Officer of Basilea, said, “These sales milestone events confirm that Cresemba conti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters